Sareum Holdings plc (LON:SAR – Get Free Report) shares crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 27.53 and traded as high as GBX 30.80. Sareum shares last traded at GBX 29.62, with a volume of 208,755 shares changing hands.
Sareum Trading Down 0.2%
The firm has a market cap of £41.76 million, a P/E ratio of -7.68 and a beta of -1.08. The business’s fifty day simple moving average is GBX 27.67 and its 200-day simple moving average is GBX 22.41.
Sareum Company Profile
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Further Reading
- Five stocks we like better than Sareum
- Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
- Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
- These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
- Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
